Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Brivanib_alaninate> ?p ?o }
- Brivanib_alaninate abstract "Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (cirrhosis) or after infection with hepatitis B or hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival.While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include chemotherapy and immunotherapy. Radiofrequency ablation and ethanol injection are also used to remove small tumors.As a result of poor liver function, metastases, or both, only 10% to 20% of patients undergo surgery. In patients having surgery, the 5-year survival rate is only 25% to 50%. Several chemotherapeutic agents have been evaluated for the treatment of hepatocellular carcinoma. Doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin), the most widely used agent in HCC, has shown a 4% to 10.5% response rate in patients with HCC. Studies have shown that the overall response (OR) rate, but not overall survival (OS), doubles when doxorubicin was given in combination with cisplatin, IFN, and 5-fluorouracil. The multitargeted tyrosine kinase inhibitor sorafenib (trade name Nexavar), which inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, raf, c-kit, and flt-3, has been shown to inhibit HCC-induced proliferation and angiogenesis. Sorafenib has also been shown to provide a significant improvement in OS in patients with HCC. Based on these results, researchers concluded that this class of agents may be effective in the treatment of HCC. Brivanib alaninate also inhibits VEGFR and fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world.".
- Brivanib_alaninate atcPrefix "none".
- Brivanib_alaninate casNumber "649735-63-7".
- Brivanib_alaninate iupacName "(S)-(R)-1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2-yl 2-aminopropanoate".
- Brivanib_alaninate pubchem "11154925".
- Brivanib_alaninate thumbnail Brivanib_alaninate.svg?width=300.
- Brivanib_alaninate wikiPageExternalLink brivanib-alaninate.
- Brivanib_alaninate wikiPageExternalLink Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81850.
- Brivanib_alaninate wikiPageExternalLink WC500117965.pdf.
- Brivanib_alaninate wikiPageExternalLink www.oncozine.com.
- Brivanib_alaninate wikiPageID "34793637".
- Brivanib_alaninate wikiPageLength "17534".
- Brivanib_alaninate wikiPageOutDegree "63".
- Brivanib_alaninate wikiPageRevisionID "675800570".
- Brivanib_alaninate wikiPageWikiLink 5-fluorouracil.
- Brivanib_alaninate wikiPageWikiLink Adriamycin.
- Brivanib_alaninate wikiPageWikiLink Angiogenesis.
- Brivanib_alaninate wikiPageWikiLink Aqueous.
- Brivanib_alaninate wikiPageWikiLink Aqueous_solution.
- Brivanib_alaninate wikiPageWikiLink Bioavailability.
- Brivanib_alaninate wikiPageWikiLink Bristol-Myers_Squibb.
- Brivanib_alaninate wikiPageWikiLink Broad-spectrum.
- Brivanib_alaninate wikiPageWikiLink Broad-spectrum_antibiotic.
- Brivanib_alaninate wikiPageWikiLink C-kit.
- Brivanib_alaninate wikiPageWikiLink CD117.
- Brivanib_alaninate wikiPageWikiLink Category:Amino_acid_derivatives.
- Brivanib_alaninate wikiPageWikiLink Category:Bristol-Myers_Squibb.
- Brivanib_alaninate wikiPageWikiLink Category:Experimental_cancer_drugs.
- Brivanib_alaninate wikiPageWikiLink Category:Indoles.
- Brivanib_alaninate wikiPageWikiLink Category:Prodrugs.
- Brivanib_alaninate wikiPageWikiLink Cetuximab.
- Brivanib_alaninate wikiPageWikiLink Chemotherapeutic_agents.
- Brivanib_alaninate wikiPageWikiLink Chemotherapy.
- Brivanib_alaninate wikiPageWikiLink Cirrhosis.
- Brivanib_alaninate wikiPageWikiLink Cisplatin.
- Brivanib_alaninate wikiPageWikiLink Colorectal_cancer.
- Brivanib_alaninate wikiPageWikiLink Cytotoxic_drugs.
- Brivanib_alaninate wikiPageWikiLink Down-regulation.
- Brivanib_alaninate wikiPageWikiLink Downregulation_and_upregulation.
- Brivanib_alaninate wikiPageWikiLink Doxorubicin.
- Brivanib_alaninate wikiPageWikiLink Endothelial_cells.
- Brivanib_alaninate wikiPageWikiLink Endothelium.
- Brivanib_alaninate wikiPageWikiLink European_Commission.
- Brivanib_alaninate wikiPageWikiLink FGFR.
- Brivanib_alaninate wikiPageWikiLink FLT1.
- Brivanib_alaninate wikiPageWikiLink Fibroblast_growth_factor.
- Brivanib_alaninate wikiPageWikiLink Fibroblast_growth_factor_receptor.
- Brivanib_alaninate wikiPageWikiLink Fluorouracil.
- Brivanib_alaninate wikiPageWikiLink Growth_inhibition.
- Brivanib_alaninate wikiPageWikiLink Hepatitis_B.
- Brivanib_alaninate wikiPageWikiLink Hepatitis_C.
- Brivanib_alaninate wikiPageWikiLink Hepatocellular_carcinoma.
- Brivanib_alaninate wikiPageWikiLink Hydrolysis.
- Brivanib_alaninate wikiPageWikiLink Hydrolyzed.
- Brivanib_alaninate wikiPageWikiLink Hydroxydaunorubicin.
- Brivanib_alaninate wikiPageWikiLink IFN.
- Brivanib_alaninate wikiPageWikiLink Immunotherapy.
- Brivanib_alaninate wikiPageWikiLink In_vivo.
- Brivanib_alaninate wikiPageWikiLink Interferon.
- Brivanib_alaninate wikiPageWikiLink International_Nonproprietary_Name.
- Brivanib_alaninate wikiPageWikiLink Investigational_New_Drug.
- Brivanib_alaninate wikiPageWikiLink Investigational_drug.
- Brivanib_alaninate wikiPageWikiLink Kinase_insert_domain_receptor.
- Brivanib_alaninate wikiPageWikiLink Liver_cancer.
- Brivanib_alaninate wikiPageWikiLink Metastases.
- Brivanib_alaninate wikiPageWikiLink Metastasis.
- Brivanib_alaninate wikiPageWikiLink Nexavar.
- Brivanib_alaninate wikiPageWikiLink Overall_survival.
- Brivanib_alaninate wikiPageWikiLink Paclitaxel.
- Brivanib_alaninate wikiPageWikiLink Pharmacodynamic.
- Brivanib_alaninate wikiPageWikiLink Pharmacodynamics.
- Brivanib_alaninate wikiPageWikiLink Pharmacokinetic.
- Brivanib_alaninate wikiPageWikiLink Pharmacokinetics.
- Brivanib_alaninate wikiPageWikiLink Platelet-derived_growth_factor_receptor.
- Brivanib_alaninate wikiPageWikiLink Prodrug.
- Brivanib_alaninate wikiPageWikiLink Radiofrequency_ablation.
- Brivanib_alaninate wikiPageWikiLink Solubility.
- Brivanib_alaninate wikiPageWikiLink Sorafenib.
- Brivanib_alaninate wikiPageWikiLink Survival_rate.
- Brivanib_alaninate wikiPageWikiLink Toxicity.
- Brivanib_alaninate wikiPageWikiLink Tyrosine-kinase_inhibitor.
- Brivanib_alaninate wikiPageWikiLink Tyrosine_kinase.
- Brivanib_alaninate wikiPageWikiLink Tyrosine_kinase_inhibitor.
- Brivanib_alaninate wikiPageWikiLink Tyrosine_kinases.
- Brivanib_alaninate wikiPageWikiLink VEGF.
- Brivanib_alaninate wikiPageWikiLink VEGFR.
- Brivanib_alaninate wikiPageWikiLink VEGFR-1.
- Brivanib_alaninate wikiPageWikiLink VEGFR-2.
- Brivanib_alaninate wikiPageWikiLink VEGFR-3.
- Brivanib_alaninate wikiPageWikiLink VEGF_receptors.
- Brivanib_alaninate wikiPageWikiLink Vascular_endothelial_growth_factor.
- Brivanib_alaninate wikiPageWikiLink Vascular_endothelial_growth_factor_receptor.
- Brivanib_alaninate wikiPageWikiLinkText "Brivanib alaninate".
- Brivanib_alaninate wikiPageWikiLinkText "Brivanib_alaninate".
- Brivanib_alaninate atcPrefix "none".
- Brivanib_alaninate c "22".
- Brivanib_alaninate casNumber "649735".
- Brivanib_alaninate chembl "270995".
- Brivanib_alaninate chemspiderid "9330033".
- Brivanib_alaninate f "1".